Pretarget lymphoma therapy
Alternative Names: Pretarget technologyLatest Information Update: 07 Apr 2004
At a glance
- Originator Poniard Pharmaceuticals
- Class Antibodies
- Mechanism of Action CD20 antigen inhibitors; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma